# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Signet ring cell carcinoma

Diffuse gastric cancer
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-7 of 7 results.
Liquid Biopsies for the Personalized Management of Patients With Hereditary Diffuse Gastric Cancer
Status: Not yet recruiting
Last Changed: Feb 05, 2020
First Received: Feb 05, 2020
Disease(s): Hereditary Diffuse Gastric Cancer
Intervention(s): Liquid biopsies (blood, gastric fluid).
XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma
Status: Not yet recruiting
Last Changed: Nov 28, 2017
First Received: Nov 28, 2017
Disease(s): Gastric Carcinoma
Intervention(s): Apatinib, XELOX
ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Study
Status: Recruiting
Last Changed: May 29, 2020
First Received: Aug 08, 2018
Disease(s): Lobular Breast Carcinoma, Gastric Cancer
Intervention(s): Crizotinib Oral Capsule [Xalkori], Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex]
Locations: Royal Marsden NHS Foundation Trust, London, United Kingdom
QUILT-3.017: Study of NEO-201 in Solid Tumors
Status: Recruiting
Last Changed: Aug 12, 2019
First Received: Mar 26, 2018
Disease(s): Colorectal Cancer, Pancreatic Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer, Breast Cancer, Mucinous Carcinoma of Ovary, Signet Ring Cell Carcinoma of Ovary
Intervention(s): NEO-201
Locations: National Cancer Institute, Bethesda, Maryland, United States
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Status: Recruiting
Last Changed: Jul 29, 2020
First Received: Dec 01, 2016
Disease(s): Adenoid Cystic Carcinoma, Adnexal Carcinoma, Apocrine Carcinoma, Extraocular Cutaneous Sebaceous Carcinoma, Hidradenocarcinoma, Keratoacanthoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Paget Disease, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Squamous Cell Carcinoma, Spiradenocarcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage III Skin Cancer, Stage IV Skin Cancer, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Intervention(s): Laboratory Biomarker Analysis, Nivolumab, Talimogene Laherparepvec
Locations: Los Angeles County-USC Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
University of Colorado Hospital, Aurora, Colorado, United States
Northwestern University, Chicago, Illinois, United States
... and 17 other locations.
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Status: Recruiting
Last Changed: Aug 07, 2020
First Received: Jan 25, 2017
Disease(s): Stomach Neoplasms, Stomach Cancer, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS), Familial Difuse Gastric Cancer, Hereditary Diffuse Gastric Cancer (HDGC)
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma
Status: Recruiting
Last Changed: Jul 10, 2019
First Received: Oct 31, 2012
Disease(s): Signet Ring Cell Gastric Adenocarcinoma
Intervention(s): peri-operative chemotherapy, Surgery first
Locations: General and digestive surgical department, Claude Huriez Hospital, University Hospital, Lille cedex, France